retatrutide clinical trials review vs Ozempic: Trial Comparisons retatrutide safety profile clinical trials

The company said the investigational GIP, GLP-1 glucagon triple hormone receptor agonist may offer another option for both diabetes and obesity

Thus, BED appears to involve GLP-1 dysregulation without consistent endocrine abnormalities, implying that GLP-1 RA therapy works through supraphysiological receptor activation and modulation of central reward circuitry, rather than by correcting a hormonal deficit [55]

Researchers did a study that lasted nearly a year with 338 adults who were not diabetic but were overweight or obese

Well, that's one of the issues, no-one quite knows

Why weight loss can simultaneously improve and complicate things Weight loss significantly boosts male sexual function

To put that into perspective, Ozempic and Wegovy are GLP-1 receptor agonists, while Zepbound and Mounjaro are dual GIP/GLP-1 receptor agonists